Retagliptin

Drug Profile

Retagliptin

Alternative Names: SP 2086

Latest Information Update: 05 May 2017

Price : $50

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antihyperglycaemics; Carboxylic acids; Fluorobenzenes; Imidazoles; Pyrazines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Submission Withdrawal Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 04 Jul 2016 Jiangsu HengRui Medicine Co. plans a phase I pharmacokinetics trial in Healthy volunteers in China (PO) (NCT02826044)
  • 01 Apr 2016 Jiangsu HengRui Medicine Co. initiates a phase I pharmacokinetics trial for Type-2 diabetes mellitus in China (PO) (NCT02822534)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top